Skin stem cells gain traction for skin repair and regeneration


Although a tremendous progress has been made, large full-thickness skin defects are still associated with mortality due to a low availability of donor skin areas.

Autologous cultured epidermal autografts (CEA) were first to be used as an epidermal substitute; however, their functional and esthetic results were unsatisfying due to graft contracture, scars, and infections. The addition of a cellular dermal component to those skin substitutes resulted in an improved function and esthetic appearance. These improvements are due to the presence of fibroblasts, which produce extracellular matrix (ECM) proteins such as collagen, elastin, laminin, and fibronectin that provide a mechanical stability to the dermis and regulate the function of cells in the epidermis, keratinocytes and melanocytes. Recently, dermo-epidermal tissue-engineered skin substitutes (DESS) emerged as an alternative in the treatment of deep burns and various skin-related disorders mimicking a near-natural skin appearance with regard to the skin texture, color, and mechanical properties.

Due to the shortage of skin donor sites following large full-thickness skin injuries, new cell sources have been exploited for skin tissue regeneration. Adipose tissue represents an abundant and easily accessible source of adult stem cells for translational clinical approaches including skin tissue engineering. The stromal vascular fraction (SVF) is a freshly isolated heterogeneous cell population, which is derived from excised adipose tissue or liposuctions. The SVF may be further used for selection and expansion of an adherent population, so-called adipose-derived stem cells (ASCs). The ASCs are characterized by the expression of specific markers and their ability to differentiate into cells from meso-, ecto-, and endodermal lineages. However, recently introduced new nomenclature, isolation protocols, culture techniques, and differentiation methods lack standardization and may lead to misunderstandings.

Adipose-derived stem cell therapy has gained tremendous interest in the area of skin repair and regeneration as a new paradigm for skin function restoration after injury. Compared to BMSCs, sufficient number of ASCs can be obtained from a relative small amount of adipose tissue during a minimally invasive harvesting procedure. Therefore, ASCs are recognized as an attractive substitute for BMSC for therapeutic applications.

However, apart from the numerous in vitro and in vivo studies demonstrating the high therapeutic potential of ASCs, the lack of standardized cell isolation methods as well as culture and differentiation protocols need to be overcome to advance the clinical utility of these cells. Moreover, additional safety studies and quality controls tests are necessary to translate scientific findings from basic science into the standard skin wound care plan in the clinic.



This report is for information purposes only, and is neither a solicitation or recommendation to buy nor an offer to sell securities. Financials Trend is not-a-registered-investment-advisor. Financials Trend is not a broker-dealer. Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. Financials Trend accepts no liability for any losses arising from an investor's reliance on the use of this material. Financials Trend sometimes gets compensated up to one hundred and fifty thousand dollars per month for featuring particular stocks. See site disclaimer for complete compensation. Financials Trend and its affiliates or officers currently hold no shares of these stocks. Financials Trend and its affiliates or officers will purchase and sell shares of common stock of these stocks, in the open market at any time without notice. Financials Trend will not update its purchases and sales of these stocks in any future postings on Financials Trend's websites. Certain information included herein is forward-looking within the context of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. The words "may", "would," "will," "expect," "estimate," "anticipate," "believe," "intend," " project," and similar expressions and variations thereof are intended to identify for ward-looking statements. Such forward- looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. *Financials Trend does not set price targets on securities. Never invest into a stock discussed on this web site or in this email alert unless you can afford to lose your entire investment.